Delhi's Patiala House Court has rejected the anticipatory bail plea of businessman Vicky Ramancha in connection with the alleged international fraud of ₹156 crore (approximately US$18.8 million) related to the anti-diabetic drug Ozempic.
Crime News: The Additional Sessions Judge's court in Patiala House, Delhi, refused to grant anticipatory bail to businessman Vicky Ramancha in the ₹156 crore (US$18.8 million) international fraud case related to the anti-diabetic drug Ozempic. Additional Sessions Judge Saurabh Laler stated that the widespread scale of the alleged fraud and the serious health risk associated with sending counterfeit drugs to the United States do not favor granting bail at this stage.
The court also commented that India's pharmaceutical industry is a strategic national asset that needs to be protected from criminal exploitation. Emphasizing that the supply of counterfeit drugs poses a direct threat to public health and safety, the court stressed that swift action against such drug crimes is necessary to maintain India's reputation as the "Pharmacy of the World" and to protect legitimate manufacturers from regulatory adversities.
Court's Strong Remarks
Additional Sessions Judge Saurabh Laler stated that India's pharmaceutical industry is a strategic national asset, which is crucial to protect from criminal exploitation. The supply of counterfeit drugs is a direct attack on public health and safety. He also clarified that swift and strict action is necessary on such crimes to maintain India's global reputation as the "Pharmacy of the World" and to protect legitimate drug manufacturers from unnecessary regulatory adversities.
Company's Allegation and Contract
US-based Assure Global LLC, in its complaint, accused Vicky Ramancha of sending counterfeit Ozempic drugs to the United States.
According to the complaint: Ramancha had a contract to supply 125,000 doses through Dubai-based RNR Premier Medical Equipments Trading LLC and US-based RNR Global Procurement Corp.
Ramancha claimed to have political connections in India and presented agreements and invoices issued by Ouchi Pharma based in China and Hong Kong. These documents were also notarized at Delhi's Patiala House Court.
FDA Action and Seizure of Drugs
The complaint stated that when the consignment of drugs reached the United States, the US Food and Drug Administration (FDA), after investigation, declared them to be counterfeit and adulterated. The FDA immediately seized all these drugs and informed the relevant authorities about the matter. The case was later handed over to the Economic Offences Wing (EOW) of the Delhi Police.
An FIR was registered on May 29, 2025, following the court's order. The EOW has started investigating all parties, companies, and transactions involved internationally. The court said that making and selling counterfeit drugs for serious illnesses like diabetes is extremely dangerous. Such drugs not only pose a threat to patients' health but also affect the effectiveness of the treatment.
